ALLO Stock Analysis: Buy, Sell, or Hold?
ALLO - Allogene Therapeutics, Inc. Common Stock
$1.93
-0.07 (-3.50%)
▼
5d:
-7.66%
30d:
+8.43%
90d:
-29.04%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
29d
Get Alerted When ALLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALLO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ALLO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ALLO is currently trading at $1.93, which is considered slightly low relative to its 30-day fair value range of $1.90 to $2.12.
Technical Outlook: Technically, ALLO is in a downtrend. The price is currently testing key support at $1.88. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: ALLO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.48 (+339.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALLO is in a downtrend. The price is currently testing key support at $1.88. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: ALLO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.48 (+339.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.90 -
$2.12
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 339.6% below Wall St target ($8.48)
- CAUTION: 5-day price weakness (-7.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.90 -
$2.12
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.88
Resistance Level
$2.25
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.82
Wall Street Target
$8.49
(+339.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Annie Yoshiyama
SELL
9586 shares
2026-04-21
Benjamin Machinas Beneski
SELL
2867 shares
2026-03-31
Benjamin Machinas Beneski
SELL
4835 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
